AutovaxID™-C introduced by Biovest International

December 08, 2005

Biovest International, Inc. (Symbol: BVTI.OB), a biopharmaceutical company focused on the development of patient specific immunotherapeutics and automated cell culture instrumentation, presented its newest cell culture instrument, the AutovaxIDTM-C, at the Cancer Research Institute's recent meeting titled "Cancer Vaccines: Barriers, Endpoints and Opportunities." This was the first introduction of the AutovaxIDTM-C to the biotech industry.

The AutovaxID-C is an automated hollow fiber cell culture instrument that collects secreted protein from cells and controls the growth of the cells automatically for 30 days or more. Growth takes place in sterile, disposable patient specific modules that are bar coded for ease of tracking and identification. Biovest believes that the AutovaxID-C instrument represents a significant advance in personalized medicine because it reduces the possibility of cross contamination and allows segregation of patient specific vaccine batches. Further expected advantages include reduced manpower requirements, automated batch record generation and improved efficiency in facility design.

"Cancer vaccines are one of the most exciting and promising fields of personalized medicine," said Carl M. Cohen, Ph.D., Chief Operating Officer, Biovest. "The production of a patient specific vaccine to immunize individuals against their own cancers has been a goal of investigators in both academia and industry. Biovest is currently testing an idiotype vaccine to treat follicular non-Hodgkin's lymphomas in a Phase 3 clinical trial."

"Our approach is unique in that it uses hybridoma technology to produce complete idiotype proteins identical to those on the tumor B cells. Results from early clinical trials are very encouraging and generating a lot of excitement in the medical community; however, there has been some concern about the challenge of producing personalized vaccines on a large scale. At this meeting we presented the first of a suite of instruments, designed and produced by the Biovest Advanced Instrumentation Division, that automates many of the steps involved in hybridoma-based manufacturing. We believe that our new instruments will facilitate the large-scale manufacture of personalized vaccines. We also believe that there is a significant market potential for this instrument," said Dr. Cohen.

About Biovest International: Biovest International, Inc. is a pioneer in the development of advanced individualized immunotherapies for life-threatening cancers of the blood system. Biovest is a majority owned subsidiary of Accentia Biopharmaceuticals, Inc. (NASDAQ: ABPI). Biovest has a foundation in the manufacture of biologics for research and for clinical trials. In addition, Biovest develops, manufactures, and markets patented cell culture systems including the AutovaxID-C which is being developed as a automated vaccine manufacturing instrument. Biovest's therapy for follicular non-Hodgkin's lymphoma, BiovaxIDTM, is currently in a Phase 3 pivotal clinical trial at over 20 major centers in the US being conducted under a Cooperative Research and Development Agreement (CRADA) with the National Cancer Institute. For further information, please visit Biovest's website: www.biovest.com
-end-
Forward-Looking Statements
Statements in this release that are not strictly historical in nature constitute "forward-looking statements." Such statements include, but are not limited to, statements about BiovaxID and AutovaxID-C and any other statements relating to Biovest's products, product candidates, and product development programs. Such statement may include, without limitation, statements with respect to the Company's plans, objectives, expectations and intentions and other statements identified by words such as "may", "could", "would", "should", "believes", "expects", "anticipates", "estimates", "intends", "plans" or similar expressions. Such forward-looking statements involve known and unknown risks, uncertainties, and other factors that may cause Biovest's actual results to be materially different from historical results or from any results expressed or implied by such forward-looking statements. These factors include, but are not limited to, risks and uncertainties related to the progress, timing, cost, and results of Biovest's clinical trials and product development programs; difficulties or delays in obtaining regulatory approval for product candidates; competition from other pharmaceutical or biotechnology companies; and the additional risks discussed in Biovest's filings with the Securities and Exchange Commission. All forward looking statements are qualified in their entirety by this cautionary statement, and Biovest undertakes no obligation to revise or update this news release to reflect events or circumstances after the date hereof.

SciWords

Related Clinical Trials Articles from Brightsurf:

Nearly 1 in 5 cancer patients less likely to enroll in clinical trials during pandemic
A significant portion of cancer patients may be less likely to enroll in a clinical trial due to the ongoing coronavirus pandemic.

COVID-19 clinical trials lack diversity
Despite disproportionately higher rates of COVID-19 infection, hospitalization and death among people of color, minority groups are significantly underrepresented in COVID-19 clinical trials.

Why we should trust registered clinical trials
In a time when we have to rely on clinical trials for COVID-19 drugs and vaccines, a new study brings good news about the credibility of registered clinical trials.

Inclusion of children in clinical trials of treatments for COVID-19
This Viewpoint discusses the exclusion of children from coronavirus disease 2019 (COVID-19) clinical trials and why that could harm treatment options for children.

Review evaluates how AI could boost the success of clinical trials
In a review publishing July 17, 2019 in the journal Trends in Pharmacological Sciences, researchers examined how artificial intelligence (AI) could affect drug development in the coming decade.

Kidney patients are neglected in clinical trials
The exclusion of patients with kidney diseases from clinical trials remains an unsolved problem that hinders optimal care of these patients.

Clinical trials beginning for possible preeclampsia treatment
For over 20 years, a team of researchers at Lund University has worked on developing a drug against preeclampsia -- a serious disorder which annually affects around 9 million pregnant women worldwide and is one of the main causes of death in both mothers and unborn babies.

Underenrollment in clinical trials: Patients not the problem
The authors of the study published this month in the Journal of Clinical Oncology investigated why many cancer clinical trials fail to enroll enough patients.

When designing clinical trials for huntington's disease, first ask the experts
Progress in understanding the genetic mutation responsible for Huntington's disease (HD) and at least some molecular underpinnings of the disease has resulted in a new era of clinical testing of potential treatments.

New ALS therapy in clinical trials
New research led by Washington University School of Medicine in St.

Read More: Clinical Trials News and Clinical Trials Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.